SANA - Why Sana Biotechnology Shares Are Rising Today | Benzinga
Sana Biotechnology, Inc. (NASDAQ: SANA) announced the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to begin a study of SC262 in patients with relapsed or refractory B-cell malignancies (initially in patients who have received prior CD19-directed CAR T therapy).
"Patients who have ...